CliffBio
small molecule

INQOVI

CEDAZURIDINE; DECITABINE

Loss of exclusivityFebruary 2041latest FDA-listed patent expiry
CompanyTaiho Oncology →See this company's full patent-cliff portfolio

Drug detail

Brand nameINQOVI
Active ingredientCEDAZURIDINE; DECITABINE
Strength100MG;35MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2020
Marketing statusRX

Listed patents

PatentExpiresType
12239653February 2041use U-2866
11963971February 2041product
12195496October 2040product
8268800August 2030substance
8618075October 2028use U-2867
9567363October 2028substance

Regulatory exclusivity

CodeExpires
ODE-316July 2027

More from Taiho Oncology

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

INQOVI patent cliff — loss of exclusivity February 2041 | CliffBio